GlassScriptPhysician profile
Julius D Tooson
NPI 1639117278
$4,246.22
in general payments reported to CMS, 2019-2025
25 companies · $720 in 2025
The $720 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $919 · 2020: $382 · 2021: $388 · 2022: $592 · 2023: $536 · 2024: $709 · 2025: $720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,964.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,082.70 | 2019-2025 | Xifaxan, Trulance |
| Abbvie INC. | $977.92 | 2019-2025 | Linzess, Viberzi, Skyrizi |
| Pfizer INC. | $623.43 | 2019-2025 | |
| Janssen Biotech, INC. | $619.53 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $249.68 | 2019-2025 | Entyvio |
| Celgene Corporation | $132.43 | 2021-2024 | Zeposia |
| Ucb, INC. | $90.96 | 2019 | |
| Concordia Pharmaceuticals INC. | $52.46 | 2019 | |
| Ardelyx, INC. | $46.24 | 2023-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $45.13 | 2022-2024 | Dificid |
| Redhill Biopharma INC. | $45.07 | 2020 | |
| Allergan, INC. | $43.27 | 2020 | |
| Braintree Laboratories, INC. | $33.87 | 2022-2024 | Sutab, Suflave |
| Ferring Pharmaceuticals INC. | $27.01 | 2020-2022 | |
| Qol Medical, LLC | $23.53 | 2025 | Sucraid |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $20.47 | 2025 | Resolution 360 Ultra Clip |
| Daiichi Sankyo INC. | $20.34 | 2021 | |
| Madrigal Pharmaceuticals | $17.32 | 2025 | Rezdiffra |
| Gilead Sciences, INC. | $15.30 | 2025 | |
| Amgen INC. | $13.96 | 2020 | |
| Aimmune Therapeutics, INC. | $13.78 | 2024 | |
| Exact Sciences Corporation | $13.62 | 2024 | Cologuard Collection Kit |
| Shire North American Group INC | $13.47 | 2019 | |
| Medtronic USA, INC. | $13.38 | 2019 | |
| Ironwood Pharmaceuticals, INC | $11.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julius Tooson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.